Bentley Laboratories LLC — FDA Warning Letter, 2026-09-17: CGMP/Finished Pharmaceuticals/Unapproved New Drug/Misbranded/Adulterated
Letter issued · posted to fda.gov .
Subject as published: CGMP/Finished Pharmaceuticals/Unapproved New Drug/Misbranded/Adulterated
TL;DR
At a glance: The FDA's Center for Drug Evaluation and Research (CDER) issued a warning letter on September 17, 2026, to Bentley Laboratories LLC (FEI 2244819, Edison, NJ) following a March 16-27, 2026 inspection, citing Current Good Manufacturing Practice (CGMP) violations under 21 CFR parts 210-211 that render finished drug products adulterated. The letter documents failures to adequately investigate out-of-specification laboratory results for multiple lots, including failure to identify root causes, implement corrective actions, and evaluate market impact; additionally, products "Geologie Acne Control Body Wash" and "Perricone MD Acne Relief Maximum Strength Spot Gel" are identified as unapproved new drugs and misbranded under sections 505(a) and 502(ee) of the FD&C Act. The firm is required to submit a comprehensive independent assessment of its investigation system and CAPA (corrective and preventive action) program remediation plan.
Argus analysis
# FDA Warning Letter Analysis: Bentley Laboratories LLC
**Company and Violations**
Bentley Laboratories LLC, a finished pharmaceutical manufacturer located in Edison, New Jersey, received a warning letter from the FDA's Center for Drug Evaluation and Research (CDER) on September 17, 2026, following an inspection conducted March 16–27, 2026. The FDA identified significant violations of Current Good Manufacturing Practice (CGMP) regulations, resulting in drug products that the agency considers adulterated. Additionally, the inspection revealed that two specific products—"Geologie Acne Control Body Wash" and "Perricone MD Acne Relief Maximum Strength Spot Gel"—are unapproved new drugs and misbranded.
**Regulatory Citations and Their Meaning**
The violations center on 21 CFR parts 210 and 211, which establish baseline manufacturing standards for finished pharmaceuticals. Specifically, Bentley failed to meet 21 CFR 211.192 by inadequately investigating out-of-specification (OOS) test results without identifying root causes or evaluating market impact. The firm also violated 21 CFR 211.84(d)(1) and 211.84(d)(2) by failing to test incoming components for identity and purity, and by not validating supplier testing reliability. These citations address foundational quality assurance: manufacturers must scientifically justify specification changes, thoroughly document investigations, and independently verify supplier data rather than relying solely on certificates of analysis. The warning letter specifically highlighted gaps in testing for high-risk contaminants in glycerin and other components.
**Response Timeline and Compliance Monitoring**
Bentley submitted an April 21, 2026 response to FDA Form 483 observations, which the agency found inadequate. The company now faces a standard 15-working-day response window to address each violation. Peer compliance officers in pharmaceutical manufacturing should monitor whether Bentley initiates independent assessments of its investigation, CAPA, and change-management systems, and whether it communicates product recalls or customer notifications. Failure to adequately remediate may trigger seizure, injunction, or import alerts.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Bentley Laboratories LLC MARCS-CMS 732028 — September 17, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA UNITED PARCEL SERVICE Reference #: 320-26-126 Product: Drugs Over-the-Counter Drugs Recipient: Recipient Name Mr. James Burke Recipient Title President Bentley Laboratories LLC 111 Fieldcrest Avenue Edison , NJ 08837-3622 United States james.burke@bentleylabs.com Issuing Office: Center for Drug Evaluation and Research (CDER) United States Secondary Issuing Offices United States September 17, 2026 WARNING LETTER Reference number: 320-26-126 To Mr. James Burke: This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) inspection of your products, processes, facilities, and records. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. FDA Inspection and Review Violations were observed and documented during an inspection of your drug manufacturing facility, Bentley Laboratories LLC, FDA Establishment Identifier (FEI) 2244819, at 111 Fieldcrest Avenue, Edison, from March 16 to 27, 2026. This inspection was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs. This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211). Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B). In addition, violations were identified and documented during a review of product labeling collected during the onsite inspection. Based on our review, “Geologie Acne Control Body Wash” and “Perricone MD Acne Relief Maximum Strength Spot Gel” are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). In addition, these products are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). As explained further below, introducing or delivering these products for introduction into interstate commerce is prohibited under sections 301(a) and 301(d) of the FD&C Act, 21 U.S.C. 331(a) and 331(d). We review…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- When did FDA issue the warning letter to Bentley Laboratories LLC?
- FDA issued the letter (MARCS-CMS 732028) on 2026-09-17 and posted it publicly on fda.gov on 2026-09-29.
- Is the FDA warning letter to Bentley Laboratories LLC publicly available?
- Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/bentley-laboratories-llc-732028-09172026.
- What does a "critical" severity rating mean for this letter?
- Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
- What is the regulatory background for a CGMP — Current Good Manufacturing Practice warning letter?
- CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). Bentley Laboratories LLC — FDA Warning Letter, 2026-09-17: CGMP/Finished Pharmaceuticals/Unapproved New Drug/Misbranded/Adulterated. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-bentley-laboratories-llc-2026-09-17-cgmp
"Bentley Laboratories LLC — FDA Warning Letter, 2026-09-17: CGMP/Finished Pharmaceuticals/Unapproved New Drug/Misbranded/Adulterated." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-bentley-laboratories-llc-2026-09-17-cgmp.
Argus HQ Research. "Bentley Laboratories LLC — FDA Warning Letter, 2026-09-17: CGMP/Finished Pharmaceuticals/Unapproved New Drug/Misbranded/Adulterated." Digital Empire Holdings LLC. Accessed September 30, 2026. https://argushq.ai/fda/warning-letter/fda-wl-bentley-laboratories-llc-2026-09-17-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_bentley_laboratories_llc_2026_09_17_cgmp_2026,
title = {Bentley Laboratories LLC — FDA Warning Letter, 2026-09-17: CGMP/Finished Pharmaceuticals/Unapproved New Drug/Misbranded/Adulterated},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-bentley-laboratories-llc-2026-09-17-cgmp},
note = {Accessed: September 30, 2026}
}